Fluoxetine disrupts cholesterol metabolism in endothelial cells via SREBP2 activation
· 1 min readNews
Source
Fluoxetine disrupts cholesterol metabolism in endothelial cells via SREBP2 activation
You might also wanna read
Karolinska Institutet study finds SSRIs affect developing nerve cell metabolism differently
A new study from Karolinska Institutet reveals that different SSRI medications affect metabolic processes in developing nerve cells in disti
Flow-mediated endothelial remodeling and inflammation drive developmental vascular susceptibility in ldlr loss of function
doi.org·1d ago
Eli Lilly's experimental gene-editing therapy VERVE-102 shows promise as one-time treatment for high cholesterol
Eli Lilly is testing VERVE-102, an experimental gene-editing therapy for high cholesterol that could be administered as a one-time infusion
Perivascular adipose single-cell atlas identifies CD55+ adipose-derived stem cells as vascular remodeling regulators in atherosclerosis
doi.org·6d ago
Membrane lipid poly-unsaturation selectively affects dopamine D2 receptor endocytosis
doi.org·1d ago

Microbial metabolite restores liver health by targeting PPARα and lipid metabolism through the gut-liver axis
This scientific research article reports on the therapeutic potential of a microbial metabolite (10-hydroxy-10-hydr) in alleviating liver in

Comments
Sign in to join the conversation.
No comments yet. Be the first.